AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17427615 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-equipped eye tray including fluorescein dye, materials for irrigation and foreign body removal, a short‐acting mydriatic agent, and topical anesthetics and antibiotics; prepared in advance for eye injuries.
Number of subjects: 0
Study 17427615 — intervention group
Group type: COMPARATOR
Intervention: Eye patching
Number of subjects: 0
Study 17427615 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention and patient counseling on proper eye protection
Number of subjects: 0
Study 17427615 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate personal protection against laser use
Number of subjects: 0
Study 17427615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection and safety counseling for outdoor workers
Number of subjects: 0
Study 17427615 — intervention group
Group type: COMPARATOR
Intervention: Contact lenses
Number of subjects: 0
Study 16470428 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial components
Number of subjects: 40
Study 16470428 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial components
Number of subjects: 40
Study 16470428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 12452939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Number of subjects: 229
Study 12452939 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Number of subjects: 229
Study 10723898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffening overtube
Number of subjects: 232
Study 10723898 — intervention group
Group type: COMPARATOR
Intervention: No overtube (control group)
Number of subjects: 232
Study 8530244 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 24
Study 8530244 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 24
Study 1837825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative task sequencing
Number of subjects: 20
Study 1837825 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspersal task sequencing
Number of subjects: 20
Study 7061155 — intervention group
Group type: COMPARATOR
Intervention: High-grade purity ampicillin (less than 0.1 microgram antigen per gram)
Number of subjects: 0
Study 7061155 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly contaminated ampicillin (1.5 microgram antigen per gram)
Number of subjects: 0
Study 7061155 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of high molecular weight proteinaceous impurities (0.1-10 micrograms of antigen) in rabbits
Number of subjects: 0
Study 7061155 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated subcutaneous injections of high molecular weight proteinaceous impurities in rabbits
Number of subjects: 0
Study 31342840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 0
Study 31342840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30099602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 186
Study 30099602 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 186
Study 30099602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and G-CSF
Number of subjects: 186
Study 27522250 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal attire
Number of subjects: 128
Study 27522250 — intervention group
Group type: COMPARATOR
Intervention: Casual attire
Number of subjects: 128
Study 25721187 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine combination (OFC) 6/25-12/50 mg/day
Number of subjects: 255
Study 25721187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 25721187 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine combination (OFC)
Number of subjects: 255
Study 23484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration during sleep
Number of subjects: 0
Study 23484632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 21718520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumio loupe, digital camera, continuous feedback from Dermatologist
Number of subjects: 60
Study 21718520 — intervention group
Group type: COMPARATOR
Intervention: Standard educational intervention (control group)
Number of subjects: 60
Study 19884625 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE‐5 inhibitors (sildenafil, vardenafil, tadalafil, mirodenafil, udenafil)
Number of subjects: 0
Study 19884625 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of specific PDE‐5 inhibitor
Number of subjects: 0
Study 19884625 — intervention group
Group type: COMPARATOR
Intervention: Hormonal blood tests or hormonal treatment
Number of subjects: 0
Study 17333244 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (CHO trial; 0.7 g CHO kg(‐1) h(‐1))
Number of subjects: 10
Study 17333244 — intervention group
Group type: COMPARATOR
Intervention: Water only (CON placebo trial)
Number of subjects: 10
Study 15496345 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation therapy (once a week for a total of 4 times)
Number of subjects: 16
Study 15496345 — intervention group
Group type: COMPARATOR
Intervention: Ordinary daily life in the reformatory (Control)
Number of subjects: 16
Study 11185023 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 144
Study 11185023 — intervention group
Group type: COMPARATOR
Intervention: Telephone counseling
Number of subjects: 144
Study 11185023 — intervention group
Group type: EXPERIMENTAL
Intervention: CO feedback (yes)
Number of subjects: 144
Study 11185023 — intervention group
Group type: COMPARATOR
Intervention: CO feedback (no)
Number of subjects: 144
Study 9008662 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg)
Number of subjects: 9
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.063% ropivacaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (1:200,000, 5 micrograms/ml)
Number of subjects: 23
Study 1286053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with epinephrine (1%, 0.5%, and 0.25%)
Number of subjects: 23
Study 1286053 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study 1286053 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 23
Study 1286053 — intervention group
Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 23
Study 3932048 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 308
Study 3932048 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms q.i.d.
Number of subjects: 308
Study 3932048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 30409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously with nivolumab 3 mg/kg intravenously on days 1 and 14, every 4 to 6 weeks
Number of subjects: 70
Study 30409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and nivolumab therapy
Number of subjects: 70
Study 30409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapy bone marrow and peripheral blood CD3 and CD8
Number of subjects: 70
Study 30409776 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4 on CD4+ Teff
Number of subjects: 70
Study 29737955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeza (flavored beverage)
Number of subjects: 66
Study 29737955 — intervention group
Group type: COMPARATOR
Intervention: Barium sulfate suspension
Number of subjects: 66
Study 29737955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeza
Number of subjects: 66
Study 27036390 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 2 weeks
Number of subjects: 200
Study 27036390 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg daily for 2 weeks
Number of subjects: 200
Study 27036390 — intervention group
Group type: COMPARATOR
Intervention: Cold compresses 2 times daily for 2 weeks
Number of subjects: 200
Study 27036390 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 200
Study 24742662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titration algorithm adjusting lispro every day (Q1D)
Number of subjects: 1106
Study 24742662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titration algorithm adjusting lispro every 3 days (Q3D)
Number of subjects: 1106
Study 24742662 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified, but implied as standard care)
Number of subjects: 1106
Study 24106244 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin monotherapy, orally
Number of subjects: 120
Study 24106244 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin with rifampin, orally
Number of subjects: 120
Study 24106244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulathromycin intramuscularly
Number of subjects: 120
Study 24106244 — intervention group
Group type: COMPARATOR
Intervention: Saline intramuscularly (placebo)
Number of subjects: 120
Study 20815872 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 0
Study 20815872 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 18754834 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants given in addition to a mood stabilizer
Number of subjects: 0
Study 18754834 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilizer alone
Number of subjects: 0
Study 16897916 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Telephonic Data Collection (ATDC) system
Number of subjects: 398
Study 16897916 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 398
Study 16897916 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interview
Number of subjects: 398
Study 16897916 — intervention group
Group type: COMPARATOR
Intervention: Written questionnaire
Number of subjects: 398
Study 14632704 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary-primary care partnership education package, with four or more visits per year by diabetes specialist nurse, dietician, or chiropodist.
Number of subjects: 411
Study 14632704 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the education package).
Number of subjects: 411
Study 11007104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 30‐60 ml/day for three months (SHE‐L)
Number of subjects: 40
Study 11007104 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no lactulose, SHE‐NL)
Number of subjects: 40
Study 8980598 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in intervention communities
Number of subjects: 98
Study 8980598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 98
Study 1632171 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 18
Study 1632171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl anaesthesia
Number of subjects: 18
Study 6933705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaF solution rinsed once every 2 weeks for 3 years
Number of subjects: 170
Study 6933705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NaF solution rinsed weekly
Number of subjects: 170
Study 6933705 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 170
Study 31654784 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT (30 Gy in 10 fractions)
Number of subjects: 194
Study 31654784 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT (37.5 Gy in 15 fractions)
Number of subjects: 194
Study 31654784 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery alone
Number of subjects: 194
Study 31563548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton thread
Number of subjects: 200
Study 31563548 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene 0
Number of subjects: 200
Study 31563548 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study 29066245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.04 mg kg−1)
Number of subjects: 12
Study 29066245 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.5 mg kg−1)
Number of subjects: 12
Study 25432953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print materials
Number of subjects: 192
Study 25432953 — intervention group
Group type: COMPARATOR
Intervention: Generic print materials
Number of subjects: 192
Study 24113432 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium with 300 mg iodine/ml
Number of subjects: 120
Study 24113432 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium with 370 mg iodine/ml
Number of subjects: 120
Study 24113432 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced PET/CT
Number of subjects: 120
Study 21859750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg
Number of subjects: 618
Study 21859750 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 618
Study 19758618 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid intravenously every 3 months for 4 treatments
Number of subjects: 93
Study 19758618 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 93
Study 17764879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubulcus multilayer bandaging system (35 mm Hg)
Number of subjects: 138
Study 17764879 — intervention group
Group type: COMPARATOR
Intervention: Multilayer bandaging system with elastic bandages only (20 to 25 mm Hg)
Number of subjects: 138
Study 16220284 — intervention group
Group type: COMPARATOR
Intervention: ESPrit 3G (W setting)
Number of subjects: 28
Study 16220284 — intervention group
Group type: COMPARATOR
Intervention: ESPrit 3G (M setting)
Number of subjects: 28
Study 16220284 — intervention group
Group type: COMPARATOR
Intervention: ESPrit 3G
Number of subjects: 28
Study 14520518 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 12
Study 14520518 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 12
Study 14520518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11561564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and metronidazole 500 mg twice daily for one week (Group A)
Number of subjects: 253
Study 11561564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus clarithromycin 250 mg and metronidazole 500 mg twice daily for one week (Group B)
Number of subjects: 253
Study 11561564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for one week (Group C)
Number of subjects: 253
Study 11561564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for 2 weeks (Group D)
Number of subjects: 253
Study 11561564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 500 mg twice daily for 2 weeks (Group E)
Number of subjects: 253
Study 7717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (Ineraid, Nucleus, or 3M/Vienna)
Number of subjects: 82
Study 2197091 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 2 weeks
Number of subjects: 197
Study 2197091 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 1 g twice daily for 2 weeks
Number of subjects: 197
Study 6243714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ether
Number of subjects: 51
Study 6243714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29448221 — intervention group
Group type: EXPERIMENTAL
Intervention: Trip-specific training
Number of subjects: 0
Study 29448221 — intervention group
Group type: COMPARATOR
Intervention: No trip-specific training (Untrained)
Number of subjects: 0
Study 29448221 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of disturbances
Number of subjects: 0
Study 26963423 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban forest walking program for 5 weeks
Number of subjects: 54
Study 26963423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 22985336 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey-impregnated dressings (MHID)
Number of subjects: 63
Study 22985336 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings (CD)
Number of subjects: 63
Study 23602059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (particle concentration 300 μg/m3)
Number of subjects: 0
Study 23602059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (300 ppb)
Number of subjects: 0
Study 23602059 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control for diesel exhaust)
Number of subjects: 0
Study 23602059 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control for ozone)
Number of subjects: 0
Study 19652968 — intervention group
Group type: EXPERIMENTAL
Intervention: mIFL combined with bevacizumab
Number of subjects: 0
Study 19652968 — intervention group
Group type: COMPARATOR
Intervention: mIFL alone
Number of subjects: 0
Study 17901955 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², bolus fluorouracil 400 mg/m², fluorouracil 46‐h continuous IV infusion 2,400 mg/m², every 2 weeks for a maximum of 12 cycles)
Number of subjects: 34
Study 17901955 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 34
Study 15753743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL/kg predicted body weight tidal volume
Number of subjects: 84
Study 15753743 — intervention group
Group type: COMPARATOR
Intervention: 12 mL/kg predicted body weight tidal volume
Number of subjects: 84
Study 12027469 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G4G genotype
Number of subjects: 460
Study 12027469 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G5G genotype
Number of subjects: 460
Study 12027469 — intervention group
Group type: EXPERIMENTAL
Intervention: 5G5G genotype
Number of subjects: 460
Study 10845393 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU + 40 mg tamoxifen (group B)
Number of subjects: 70
Study 10845393 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU + 100 mg tamoxifen (group C)
Number of subjects: 70
Study 10845393 — intervention group
Group type: COMPARATOR
Intervention: BCNU alone (control group A)
Number of subjects: 70
Study 7577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 7577211 — intervention group
Group type: COMPARATOR
Intervention: Palliative expectant management
Number of subjects: 0
Study 7577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 0
Study 7577211 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional outcome measure
Number of subjects: 0
Study 1827378 — intervention group
Group type: EXPERIMENTAL
Intervention: protamine‐soluble mixture
Number of subjects: 17
Study 1827378 — intervention group
Group type: COMPARATOR
Intervention: Zn‐soluble combination
Number of subjects: 17
Study 7009310 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 13
Study 31907649 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based rehabilitation group (KBRG)
Number of subjects: 40
Study 31907649 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy group (SPTG)
Number of subjects: 40
Study 30641678 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet for 12 weeks
Number of subjects: 80
Study 30641678 — intervention group
Group type: COMPARATOR
Intervention: Diabetic diet for 12 weeks (control group)
Number of subjects: 80
Study 30641678 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 80
Study 30641678 — intervention group
Group type: COMPARATOR
Intervention: Diabetic diet (control group)
Number of subjects: 80
Study 27886522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (100mg)
Number of subjects: 3
Study 27886522 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (4.5mg)
Number of subjects: 3
Study 25884846 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 15
Study 25884846 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill meal
Number of subjects: 15
Study 25884846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 15
Study 23539076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold condition (‐14° C)
Number of subjects: 14
Study 23539076 — intervention group
Group type: COMPARATOR
Intervention: Moderate condition (6° C)
Number of subjects: 14
Study 21293122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 4 weeks
Number of subjects: 16
Study 21293122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 3 weeks
Number of subjects: 16
Study 21293122 — intervention group
Group type: EXPERIMENTAL
Intervention: QLF (Quantitative Light Fluorescence)
Number of subjects: 16
Study 19200537 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded conditions (fast speeded, moderately speeded)
Number of subjects: 0
Study 19200537 — intervention group
Group type: COMPARATOR
Intervention: Control items (unspeeded condition)
Number of subjects: 0